Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Consensus Recommendation of “Buy” from Analysts

Theravance Biopharma, Inc. (NASDAQ:TBPH) has been assigned an average rating of “Buy” from the seven brokerages that are covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a hold rating, three have issued a buy rating and two have issued a strong buy rating on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $27.80.

Several equities research analysts recently issued reports on TBPH shares. HC Wainwright upped their price target on Theravance Biopharma from $15.00 to $20.00 and gave the company a “buy” rating in a research report on Tuesday, November 11th. Weiss Ratings reissued a “hold (c)” rating on shares of Theravance Biopharma in a report on Wednesday, October 8th. Wall Street Zen downgraded shares of Theravance Biopharma from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 3rd. Oppenheimer assumed coverage on shares of Theravance Biopharma in a report on Wednesday, December 3rd. They issued an “outperform” rating and a $27.00 price target for the company. Finally, BTIG Research upped their target price on Theravance Biopharma from $25.00 to $40.00 and gave the company a “buy” rating in a report on Wednesday, November 26th.

Insiders Place Their Bets

In other Theravance Biopharma news, SVP Rhonda Farnum sold 31,067 shares of the firm’s stock in a transaction on Wednesday, December 3rd. The stock was sold at an average price of $18.75, for a total value of $582,506.25. Following the sale, the senior vice president directly owned 277,695 shares in the company, valued at approximately $5,206,781.25. This trade represents a 10.06% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 6.90% of the stock is owned by corporate insiders.

Institutional Trading of Theravance Biopharma

A number of large investors have recently modified their holdings of TBPH. Arrowstreet Capital Limited Partnership bought a new stake in Theravance Biopharma in the 3rd quarter valued at about $10,611,000. Assenagon Asset Management S.A. increased its stake in shares of Theravance Biopharma by 1,629.4% in the third quarter. Assenagon Asset Management S.A. now owns 414,715 shares of the biopharmaceutical company’s stock valued at $6,055,000 after purchasing an additional 390,735 shares during the period. Hillsdale Investment Management Inc. acquired a new stake in shares of Theravance Biopharma in the third quarter valued at approximately $4,536,000. Jefferies Financial Group Inc. raised its holdings in shares of Theravance Biopharma by 1,191.9% during the second quarter. Jefferies Financial Group Inc. now owns 276,887 shares of the biopharmaceutical company’s stock valued at $3,054,000 after buying an additional 255,455 shares during the last quarter. Finally, Two Sigma Investments LP boosted its position in shares of Theravance Biopharma by 1,199.9% during the third quarter. Two Sigma Investments LP now owns 231,272 shares of the biopharmaceutical company’s stock worth $3,377,000 after buying an additional 213,480 shares during the period. Institutional investors and hedge funds own 99.10% of the company’s stock.

Theravance Biopharma Stock Performance

Shares of Theravance Biopharma stock opened at $20.61 on Thursday. Theravance Biopharma has a 1 year low of $7.90 and a 1 year high of $20.69. The firm’s 50-day simple moving average is $18.39 and its 200-day simple moving average is $14.94. The firm has a market cap of $1.04 billion, a PE ratio of 36.16 and a beta of 0.14.

Theravance Biopharma (NASDAQ:TBPH) last announced its quarterly earnings data on Monday, November 10th. The biopharmaceutical company reported $0.07 earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.10. Theravance Biopharma had a return on equity of 12.20% and a net margin of 36.53%.The firm had revenue of $19.99 million during the quarter, compared to analyst estimates of $19.89 million. On average, equities analysts predict that Theravance Biopharma will post -1.09 earnings per share for the current year.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.